Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HRS9531 vs semaglutide in obesity
CTR20254840Phase 3Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Dec 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of HRS9531 in obesity, sponsored by Fujian Shengdi Pharmaceuticals. Started Dec 2025; status: active.
02
Drugs
HRS9531
03
Conditions
obesity
Beyond the preview
Go deeper on CTR20254840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254840.